

9

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.


Dated: March 11, 2003

Signature:

Thomas J. Wrona, Ph.D.

Docket No.: 27373/36638A
(PATENT)

K.T.
5/20
C



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Weichselbaum, et al.

Application No.: 09/964,042

Group Art Unit: 1635

Filed: September 26, 2001

Examiner: J. E. Angell

For: Treatment of Tumors with Genetically
Engineered Herpes Virus

**AMENDMENT AND RESPONSE TO THE OFFICE ACTION
OF OCTOBER 11, 2002**

Commissioner for Patents
Washington, DC 20231

RECEIVED

APR 22 2003

Dear Sir:

OFFICE OF PETITIONS

In an Office Action dated October 11, 2002, pending claims 1 through 9 were rejected under 35 USC §112, first and second paragraphs. In view of the amendments and remarks made herein, reconsideration is respectfully requested.

I. AMENDMENT

In the Specification

Please replace the text inserted before the first line by preliminary amendment on September 26, 2001 with the following:

-This is a Continuation of U.S. application Serial No. 09/629,021, filed July 31, 2000, now abandoned, which is a Continuation of U.S. application Serial No. 09/244,748, filed February 5, 1999, now abandoned.

In the Claims

Please amend claim 1 as indicated below.

1. [Twice Amended] A method for reducing tumor mass comprising the step of administering to an individual suffering from cancer an amount of a Herpes simplex